The Use of Intraperitoneal Ropivacaine in Bariatric Bypass Surgery

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study in a randomized, controlled, double-blinded format and will evaluate the ability of a local anesthetic, Ropivacaine, to decrease pain after gastric bypass surgery. The drug will be administered into the abdomen during a bariatric bypass surgery. After surgery, patients who received Ropivacaine will be compared to those without Ropivacaine to determine its effect on reducing pain, recovery of lung function, ability to walk, and quality of life during recovery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Hospital Research Institute
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• Patients undergoing Roux-en-Y gastric bypass surgery;

• Patients who able to tolerate general anesthetic and pneumoperitoneum;

• Patients who able to provide informed consent for the surgery;

• Patients over the age of 18 years;

Exclusion Criteria:

• Patient undergoing planned Sleeve Gastrectomy (inta-op conversion to Sleeve Gastrectomy after delivery of intraperitoneal ropivacaine will be included and analyzed using intention-to-treat approach)

• Patients with an allergy to local anesthetics

• Patients with severe underlying cardiovascular disease (ie: congestive heart failure, conduction abnormalities, and ischemic heart disease)

• Patients with chronic renal disease Stage 3 or greater (Creatinine clearance less than 60mL/hr (millilitre per hour))

• Patients with hepatic dysfunction Child-Pugh Class B or C

• Patients with previous foregut surgery including esophageal, gastric, liver, and pancreas resections